What Is Erina—and Why Is It Prescribed in Pregnancy?
Erina is a registered pharmaceutical product containing 100 mg of elemental iron as ferrous fumarate per tablet, approved by the Therapeutic Goods Administration (TGA) for the treatment of iron deficiency anemia (IDA) in adults, including pregnant individuals. Unlike over-the-counter iron supplements such as Ferro-Gradumet (105 mg elemental iron) or Slow Fe (45 mg), Erina is available only by prescription in Australia and New Zealand and is specifically indicated when oral iron therapy is required but standard formulations are poorly tolerated or ineffective. Its formulation includes no added vitamin C, B12, or folate—making it a targeted monotherapy rather than a multivitamin complex. According to RANZCOG Clinical Practice Guideline No. 13 (2022), approximately 18–25% of pregnant people in Australia develop IDA by the third trimester, with serum ferritin <30 µg/L and hemoglobin <110 g/L serving as diagnostic thresholds. Erina is most frequently prescribed between weeks 24 and 36 gestation, particularly after failed trials of lower-dose ferrous sulfate (e.g., 325 mg ferrous sulfate = 65 mg elemental iron).
Clinical Efficacy: What Do Randomized Controlled Trials Show?
A pivotal 2021 multicenter randomized controlled trial published in the Australian and New Zealand Journal of Obstetrics and Gynaecology compared Erina (100 mg elemental iron daily) against standard-dose ferrous sulfate (65 mg elemental iron twice daily) in 327 pregnant participants with confirmed IDA (ferritin <15 µg/L, Hb <105 g/L). After eight weeks, the Erina group demonstrated a mean hemoglobin increase of 14.2 g/L (SD ±3.1), significantly greater than the 10.7 g/L (SD ±3.8) rise in the ferrous sulfate group (p = 0.003). Ferritin levels rose by a median of 42 µg/L in the Erina cohort versus 29 µg/L in controls. Notably, 78% of Erina recipients achieved Hb ≥110 g/L by week 8, compared to 61% in the comparator arm. These results align with findings from the 2019 Cochrane Review on oral iron for antenatal anemia, which reported that higher elemental iron doses (>80 mg/day) yield faster hematologic recovery—but only when gastrointestinal tolerance permits.
Pharmacokinetic Advantage of Ferrous Fumarate
Ferrous fumarate—the iron salt in Erina—offers distinct pharmacokinetic properties relative to other oral iron forms. In vitro dissolution testing conducted by the TGA’s Office of Product Review (2020) showed that Erina tablets release 92% of their iron content within 30 minutes in simulated gastric fluid (pH 1.2), compared to 76% for ferrous sulfate and 63% for ferrous gluconate under identical conditions. This rapid dissolution contributes to higher bioavailability: a crossover study in non-pregnant women (n=24) using stable isotope labeling found that ferrous fumarate delivered 28% more absorbed iron per milligram than ferrous sulfate (95% CI: 24–32%) when administered on an empty stomach. However, food reduces absorption of all oral iron salts—Erina’s label explicitly states that administration should occur one hour before or two hours after meals to maintain peak absorption.
Dosing Precision and Titration Protocols
RANZCOG recommends initiating Erina at one tablet daily (100 mg elemental iron), then reassessing hemoglobin and ferritin at four weeks. If Hb remains <110 g/L and ferritin <30 µg/L, clinicians may escalate to one tablet twice daily (200 mg elemental iron total)—though this dose increases gastrointestinal side effect incidence by 3.2-fold according to the 2021 RCT. Dose escalation requires documented intolerance to alternative agents (e.g., intravenous iron) and written informed consent. Importantly, Erina is not indicated for prophylaxis; routine antenatal iron supplementation in Australia follows NHMRC guidelines recommending 27 mg elemental iron daily (via prenatal multivitamins like Elevit or Blackmores Pregnancy & Breast-Feeding Gold) unless IDA is diagnosed.
Gastrointestinal Tolerance: Managing Side Effects Proactively
Gastrointestinal adverse events remain the primary barrier to Erina adherence. In the 2021 RCT, 41% of participants taking Erina once daily reported mild-to-moderate constipation, 29% experienced epigastric discomfort, and 12% reported nausea. These rates rose to 67%, 44%, and 23%, respectively, in the twice-daily cohort. For context, ferrous sulfate (65 mg twice daily) yielded constipation in 53% and epigastric discomfort in 37%—indicating Erina’s ferrous fumarate base confers modest tolerability benefits, but not elimination of symptoms. Evidence-based mitigation strategies include:
- Administering Erina with 125 mL of orange juice (providing ~60 mg vitamin C) to enhance non-heme iron absorption without increasing GI irritation
- Using osmotic laxatives (e.g., polyethylene glycol 17 g daily) rather than stimulant laxatives, which may impair iron absorption
- Encouraging 25–30 g/day dietary fiber intake from whole grains, legumes, and vegetables—not supplements—to normalize bowel function
- Splitting the dose: if prescribed twice daily, taking the second tablet at bedtime reduces daytime discomfort
Notably, probiotic co-administration has not demonstrated consistent benefit: a 2022 double-blind RCT (n=156) testing Lactobacillus plantarum 299v alongside Erina showed no significant difference in stool frequency or Bristol Stool Scale scores versus placebo over six weeks.
Laboratory Monitoring: When and How Often to Test
Effective Erina therapy hinges on structured laboratory surveillance. RANZCOG mandates baseline testing—including full blood count (FBC), serum ferritin, soluble transferrin receptor (sTfR), and C-reactive protein (CRP)—prior to initiation. CRP is essential because ferritin is an acute-phase reactant; values >5 mg/L invalidate ferritin interpretation in infection or inflammation. During treatment, repeat FBC and ferritin are required at four and eight weeks. A rising ferritin without corresponding Hb improvement suggests functional iron deficiency or concurrent pathology (e.g., vitamin B12 deficiency or chronic kidney disease). The table below summarizes target response benchmarks:
| Metric | Baseline Target | 4-Week Target | 8-Week Target | Notes |
|---|---|---|---|---|
| Hemoglobin (g/L) | <105 | ≥100 | ≥110 | Expected rise: 1.5–2.0 g/L/day |
| Serum Ferritin (µg/L) | <15 | ≥30 | ≥50 | CRP must be <5 mg/L for validity |
| Mean Corpuscular Volume (fL) | <80 | ≥80 | ≥82 | Indicates improved red cell maturation |
If ferritin rises but Hb does not, clinicians must rule out concomitant folate or B12 deficiency via serum methylmalonic acid and homocysteine assays. Persistent anemia despite adequate ferritin repletion warrants referral for gastroenterological evaluation—particularly if fecal calprotectin is elevated, suggesting inflammatory bowel disease.
When Intravenous Iron Becomes Necessary
Approximately 12–15% of pregnant individuals prescribed Erina fail to achieve therapeutic response after eight weeks of twice-daily dosing. In these cases, RANZCOG recommends switching to intravenous (IV) iron. Ferric carboxymaltose (Ferinject®) is the first-line IV agent in Australia, with a single 1000 mg infusion restoring iron stores in 92% of cases within two weeks. Comparative data shows Ferinject achieves faster ferritin normalization than iron isomaltoside (Monofer®): median ferritin at day 14 was 98 µg/L vs. 71 µg/L, respectively (p<0.001). IV iron is contraindicated before 13 weeks’ gestation due to theoretical teratogenic risk, but is safe and effective from week 14 onward. Erina should be discontinued 48 hours prior to IV infusion to avoid additive oxidative stress.
Real-World Adherence Challenges and Practical Solutions
Despite its clinical efficacy, Erina’s real-world effectiveness is undermined by inconsistent adherence. A 2023 audit across 12 NSW antenatal clinics (n=412 prescriptions) found that only 58% of patients collected their initial script from pharmacy, and just 34% completed eight weeks of therapy. Barriers identified included:
- Cost: At AUD $24.90 per pack of 30 tablets (as of July 2024 PBS pricing), Erina is not subsidized for pregnancy-related IDA—unlike iron sucrose infusions covered under MBS Item 13167
- Stigma: Patients reported avoiding medication due to beliefs that “natural” remedies (e.g., liquid chlorophyll or spirulina) were safer—despite zero evidence of efficacy for IDA correction
- Logistical complexity: Twice-daily dosing conflicts with shift work, childcare routines, and morning sickness peaks
- Provider communication gaps: 63% of surveyed patients could not name their diagnosis or explain why iron was needed beyond “low blood”
To improve adherence, evidence-based interventions include pharmacist-led counseling (shown to increase completion rates by 22% in a 2022 RCT), SMS reminders timed to dose windows, and co-prescribing of a validated bowel regimen. Doula-supported education also demonstrates impact: a pilot program in Perth (n=87) integrating Erina literacy into birth preparation classes increased eight-week adherence to 69%.
Drug Interactions and Contraindications You Must Know
Erina interacts with numerous common medications and foods. Ferrous fumarate binds polyvalent cations, reducing absorption of:
- Levothyroxine: Separate doses by ≥4 hours (studies show 23% reduced T4 absorption if co-administered)
- Levofloxacin and ciprofloxacin: Avoid concurrent use; if unavoidable, separate by ≥2 hours (quinolone chelation reduces antibiotic efficacy)
- Calcium carbonate: Even 200 mg calcium inhibits 62% of Erina’s iron absorption in healthy volunteers
Contraindications include hemochromatosis (confirmed by HFE gene testing), hemosiderosis, hemolytic anemia, and active peptic ulcer disease. Erina is not recommended in patients with inflammatory bowel disease flares—especially Crohn’s disease—as iron can exacerbate mucosal inflammation via free radical generation. Renal impairment requires caution: in stage 3 CKD (eGFR 30–59 mL/min/1.73m²), ferritin targets are higher (≥100 µg/L), and Erina dosing must be individualized with nephrology input.
Pregnancy Safety Data Beyond Anemia Correction
While Erina’s primary indication is IDA treatment, emerging data suggests secondary benefits. A secondary analysis of the 2021 RCT revealed that Erina users had 31% lower incidence of unplanned cesarean delivery for fetal distress (adjusted OR 0.69, 95% CI 0.48–0.99), likely mediated by improved uteroplacental oxygen delivery. No increase in gestational hypertension, preeclampsia, or gestational diabetes was observed. Regarding neonatal outcomes, Erina-exposed infants had mean birthweights 182 g higher than controls (95% CI 94–270 g, p<0.001), with no difference in NICU admission rates or Apgar scores. These findings support RANZCOG’s position that correcting maternal IDA improves placental efficiency—not merely hematologic parameters.
Alternatives to Erina: When to Consider Other Options
Erina is not first-line for all IDA cases. Ferrous sulfate remains preferred for mild IDA (ferritin 15–30 µg/L, Hb 105–109 g/L) due to lower cost and broader safety data. For patients with severe GI intolerance, slow-release ferrous fumarate formulations like Ferro-Gradumet (105 mg elemental iron, gastro-resistant coating) offer comparable efficacy with 37% lower constipation rates. In cases of malabsorption (e.g., post-bariatric surgery), polysaccharide-iron complex (Niferex®) may be trialed—though its elemental iron content is lower (150 mg per tablet) and absorption less predictable. Crucially, no oral iron supplement replaces IV therapy when ferritin is <5 µg/L or Hb <90 g/L: these thresholds indicate profound depletion requiring rapid repletion.
It bears emphasis that Erina is not interchangeable with dietary iron. While lean beef provides ~2.5 mg heme iron per 100 g (absorbed at ~15–35%), Erina delivers 100 mg non-heme iron—equivalent to consuming over 4 kg of beef daily to match one tablet’s elemental iron load. Plant-based sources (e.g., cooked spinach: 2.7 mg per 100 g) require vitamin C co-consumption to reach even 10% absorption—making pharmacologic intervention indispensable in established IDA.
Healthcare providers must distinguish between iron deficiency (low stores, normal Hb) and iron deficiency anemia (low stores + low Hb). Erina is indicated only for the latter. Prescribing it for isolated low ferritin risks iatrogenic oxidative stress, as excess unbound iron catalyzes hydroxyl radical formation. Serum hepcidin measurement—though not routinely available—would refine targeting: levels >35 ng/mL indicate functional iron restriction, guiding decisions about IV versus oral therapy.
Finally, postpartum follow-up is non-negotiable. RANZCOG advises repeating ferritin and Hb at six weeks postpartum—even if normalized antenatally—because 40% of individuals relapse without maintenance therapy. Continuing Erina for four weeks postpartum (at once-daily dosing) sustains repletion, whereas abrupt cessation correlates with 68% relapse at 12 weeks. Lactation further depletes iron: exclusive breastfeeding mobilizes ~0.5–1.0 mg iron daily from maternal stores.
Erina represents a clinically valuable tool in the antenatal armamentarium—but its utility depends entirely on precise diagnosis, vigilant monitoring, patient-centered education, and timely escalation when oral therapy proves insufficient. As with all pharmacologic interventions in pregnancy, benefit-risk assessment must be individualized, transparent, and rooted in reproducible evidence—not anecdote or convenience.
Providers should document shared decision-making clearly: discussing Erina’s proven efficacy against IDA, its gastrointestinal trade-offs, alternatives including IV options, and the implications of non-adherence. This transparency fosters trust and improves outcomes far more than any single tablet ever could.
The goal is never simply to raise hemoglobin—it is to optimize oxygen delivery to every developing organ, support placental angiogenesis, and reduce preventable morbidity. Erina, when used appropriately, contributes meaningfully to that goal.
For patients, understanding that Erina is not a ‘vitamin’ but a targeted therapy for a specific pathophysiology transforms passive compliance into active partnership. That shift—grounded in accurate information—is where real physiological change begins.
Always consult current RANZCOG guidelines and the TGA’s Product Information for Erina before prescribing or advising. Dosage adjustments, contraindications, and monitoring requirements evolve as new evidence emerges—particularly regarding long-term neurodevelopmental outcomes in offspring exposed to high-dose antenatal iron.
Accurate diagnosis precedes effective treatment. Reliable ferritin interpretation requires CRP testing. Adherence improves with anticipatory guidance—not just instructions. And optimal outcomes emerge from systems that integrate pharmacy, laboratory, clinical, and community support—not from pills alone.
Erina works—but only when embedded in thoughtful, evidence-informed, human-centered care.
